Based on the Xvivo Perfusion AB (publ) stock forecast from 0 analysts, the average analyst target price for Xvivo Perfusion AB (publ) is not available over the next 12 months. Xvivo Perfusion AB (publ)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Xvivo Perfusion AB (publ) is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Xvivo Perfusion AB (publ)’s stock price was USD 41.10. Xvivo Perfusion AB (publ)’s stock price has changed by -4.20% over the past week, -0.32% over the past month and +80.26% over the last year.
No recent analyst target price found for Xvivo Perfusion AB (publ)
No recent average analyst rating found for Xvivo Perfusion AB (publ)
Company Overview Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden. Read Less
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Eur...Read More
Frequently Asked Questions About Xvivo Perfusion AB (publ) (XVIPF) Stock
Stock Target Advisor's fundamental analysis for Xvivo Perfusion AB (publ)'s stock is Slightly Bullish .
Unfortunately we do not have enough data on XVIPF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XVIPF's stock to indicate what its average analyst target is.
XVIPF stock's Price/Earning ratio is 71.50.
Our analysis grades XVIPF stock's Price / Earning ratio at F. This means that XVIPF stock's Price/Earning ratio is above 80% of the stocks in the Medical Devices sector in the OTC exchange.
Based on this XVIPF may be a overvalued for its sector.
The last closing price of XVIPF's stock was USD 41.10.
The most recent market capitalization for XVIPF is USD 1.35B.
Unfortunately we do not have enough analyst data on XVIPF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Xvivo Perfusion AB (publ)'s stock.
As per our most recent records Xvivo Perfusion AB (publ) has 161 Employees.
Xvivo Perfusion AB (publ)'s registered address is Gemenskapens gata 9, Mölndal, Sweden, 431 53.
You can get more information about it from Xvivo Perfusion AB (publ)'s website at https://www.xvivogroup.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Xvivo Perfusion AB (publ) (XVIPF) Stock
Stock Target Advisor's fundamental analysis for Xvivo Perfusion AB (publ)'s stock is Slightly Bullish .
Unfortunately we do not have enough data on XVIPF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XVIPF's stock to indicate what its average analyst target is.
XVIPF stock's Price/Earning ratio is 71.50.
Our analysis grades XVIPF stock's Price / Earning ratio at F. This means that XVIPF stock's Price/Earning ratio is above 80% of the stocks in the Medical Devices sector in the OTC exchange.
Based on this XVIPF may be a overvalued for its sector.
The last closing price of XVIPF's stock was USD 41.10.
The most recent market capitalization for XVIPF is USD 1.35B.
Unfortunately we do not have enough analyst data on XVIPF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Xvivo Perfusion AB (publ)'s stock.
As per our most recent records Xvivo Perfusion AB (publ) has 161 Employees.
Xvivo Perfusion AB (publ)'s registered address is Gemenskapens gata 9, Mölndal, Sweden, 431 53.
You can get more information about it from Xvivo Perfusion AB (publ)'s website at https://www.xvivogroup.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XVIPF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
